Gabelli Research Experts Lift Revenue Estimation for Pain Therapeutics, Inc. (Target PriceIE)

Gabelli Research Experts Lift Revenue Estimation for Pain Therapeutics, Inc. (Target PriceIE)

Pain Therapeutics, Inc. (NASDAQ:PTIE) – Research analysts at Gabelli upped their FY2017 earnings estimates for Pain Therapeutics in a note issued to investors on Thursday. Gabelli analyst K. Kedra now forecasts that the brokerage will post earnings of ($0.40) per share for the year, up from their prior estimate of ($0.45). Gabelli also issued estimates for Pain Therapeutics’ FY2018 earnings at ($0.55) EPS, FY2019 earnings at ($0.75) EPS and FY2020 earnings at ($0.55) EPS.

Separately, Zacks Investment Research lowered Pain Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, November 30th.

Pain Therapeutics (NASDAQ:PTIE) opened at 0.9201 on Monday. The stock’s market cap is $42.45 million. The stock has a 50 day moving average price of $0.67 and a 200-day moving average price of $0.81. Pain Therapeutics has a one year low of $0.51 and a one year high of $3.00.

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Gabelli Funds LLC raised its position in shares of Pain Therapeutics by 9.4% in the fourth quarter. Gabelli Funds LLC now owns 175,000 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 15,000 shares during the last quarter. BVF Inc. IL raised its position in shares of Pain Therapeutics by 6.0% in the third quarter. BVF Inc. IL now owns 2,278,552 shares of the biopharmaceutical company’s stock valued at $2,278,000 after buying an additional 128,639 shares during the last quarter. Spark Investment Management LLC acquired a new position in shares of Pain Therapeutics during the third quarter valued at $119,000. Finally, Acadian Asset Management LLC raised its position in shares of Pain Therapeutics by 26.3% in the third quarter. Acadian Asset Management LLC now owns 443,430 shares of the biopharmaceutical company’s stock valued at $444,000 after buying an additional 92,358 shares during the last quarter. Institutional investors own 44.34% of the company’s stock.

Pain Therapeutics Company Profile

Pain Therapeutics, Inc is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company’s lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company’s other products is FENROCK.

Related posts

Leave a Comment